Home / Health / Rare Brain Cancer Vanquished by Experimental Drugs

Rare Brain Cancer Vanquished by Experimental Drugs

Summary

  • Joscelyne Kerr, 20, battled a rare brain cancer diagnosed in 2023.
  • Experimental drugs led to remarkable results, dissolving her tumor.
  • She now champions Brain Tumour Research's Christmas Appeal.
Rare Brain Cancer Vanquished by Experimental Drugs

A young astrophysics student, Joscelyne Kerr, 20, has defied grim predictions after a rare brain cancer diagnosis in 2023. Initially fearing she wouldn't see another Christmas, Joscelyne underwent high-risk surgery and aggressive treatments that proved ineffective against her anaplastic pleomorphic xanthoastrocytoma (APXA).

Her life took a dramatic turn with a drugs trial, which delivered astonishing results and effectively dissolved the tumor. Despite a small anomaly on her latest scan, Joscelyne is living life to the fullest and focusing on enjoying precious moments with loved ones.

Now, Joscelyne is an advocate for the Brain Tumour Research Christmas Appeal, aiming to fund pioneering research and raise awareness. Her experience underscores the critical need for increased funding in brain tumor research, which receives a fraction of national cancer research expenditure.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Joscelyne Kerr was diagnosed with anaplastic pleomorphic xanthoastrocytoma (APXA), a rare form of brain cancer.
She responded remarkably well to an experimental drugs trial that successfully dissolved her tumor.
It's a campaign asking for donations to fund pioneering research into finding a cure for brain tumors.

Read more news on